Objective: To describe the pregnancy and neonatal outcomes of women receiving 17alpha-hydroxyprogesterone to prevent subsequent preterm birth in our institution.
Methods: Forty-two patient received treatment by VITA healthcare and their charts were reviewed for results and outcomes.
Results: An increase in average gestational age at the time of delivery was noticed as well as an increase in weeks gained compared to previous preterm birth.
Discussion: More than 75% of the patients prolonged their pregnancy with the use of 17alpha-hydroxyprogesterone. Continuation of the study and stratifying patients will help in identifying other risk factors and establishing criteria for improved prevention of preterm birth and prognosis.